Key points from article :
A new blood-based cancer screening test called Trucheck has been launched in Ireland, promising to detect up to 84% of cancers that cause fatalities. Developed by health testing provider Certior Health, the test can identify 70 different solid tumour types, which together account for 81% of all cancer cases and 84% of cancer-related deaths in Europe. The test is priced at around €1,500 and is expected to be offered through some corporate health programmes and insurance plans, rather than as a routine public screening tool.
Trucheck works by detecting circulating tumour cells (CTCs)—cancer cells that break away from tumours and enter the bloodstream. Because these cells can appear early in the disease process, the test aims to spot cancers before symptoms develop, as well as in more advanced stages. Unlike traditional screening methods that focus on one organ at a time, Trucheck is approved for both single-organ and multi-organ cancer screening.
According to Maggie Malone, Chief Executive Officer of Certior Health, the test represents a significant advance in early cancer detection. She says the technology has been validated using data from more than 40,000 individuals, supporting its ability to identify a wide range of cancers accurately and safely. While no academic journal publication or lead research author is cited, the company positions the test as a major step forward in broad, early cancer screening.
Certior Health is a relatively new company that initially built its reputation providing Covid-19 testing, delivering over 500,000 tests to consumers and businesses. With Trucheck, it is now expanding into oncology, reflecting growing interest in blood-based “liquid biopsy” approaches that could transform how cancer is detected and managed in the future.
